Fouad Namouni

Fouad Namouni

Pharma

BMS racks up Opdivo combo data to sell its new biomarker

Bristol-Myers Squibb has new data to support the notion that its new biomarker can help predict who can best benefit from I-O combos.

Carly Helfand Jun 4, 2018 6:59am

opdivo

BMS gets Opdivo into FDA fast lane for new melanoma use

Oct 18, 2017 11:14am